Emerging Therapies for Multiple Sclerosis

Dr. David Johnson is an internationally recognized expert in medical oncology and translational cancer research. With over 25 years of clinical and academic experience, he has led groundbreaking studies in precision oncology, immunotherapy, and molecular diagnostics. Dr. Johnson earned his medical degree from Stanford University and completed his residency and fellowship at MD Anderson Cancer Center, where he also earned a PhD in Molecular Biology. Currently serving as Chief Medical Officer at Summit Cancer Institute, Dr. Johnson oversees advanced clinical programs that integrate genomic profiling and data-driven treatment pathways. He is best known for pioneering several biomarker-driven clinical trials that have reshaped treatment algorithms in colorectal and lung cancers. His work has been published in leading journals such as The New England Journal of Medicine, JAMA Oncology, and Nature Medicine. Beyond his research and leadership roles, Dr. Johnson is a sought-after speaker and educator, having presented at ASCO, ESMO, and AACR. He also serves on the editorial boards of multiple oncology publications and advisory panels for the FDA and NIH. Dr. Johnson is passionate about advancing health equity in cancer care and mentoring the next generation of physician-scientists.